Incanthera, the drug development and targeted cancer medicines company, (“Incanthera” or “the Company”), is pleased to announce the appointment of Laura Brogden, to Chief Financial Officer of the Company with immediate effect.
Laura, an Associate of the Chartered Institute of Management Accounts since 2006, joins the Board with 17 years’ industry experience.
Laura is currently a Senior Accountant at summ.it, a commercially focused specialist accountancy firm delivering exceptional internal systems for small and medium sized businesses.
Her position with summ.it since 2006, has been the responsibility for a portfolio of entrepreneurial clients within a Finance Director role, her clients covering a diverse range of ambitious and fast paced industries. Laura’s position has provided extensive experience with Venture Capital funded businesses as well as private equity, several within the Biotech industry, including over 5 years’ heading the finance team for Incanthera, requiring direct contribution at board level.
Commenting on Laura’s appointment, Simon Ward, Chief Executive of Incanthera said:
“Laura is a fantastic addition to the Incanthera team. As someone well known to us through heading the finances for Incanthera at summ.it, we are delighted that she has accepted the position of Chief Financial Offer within the Company and the Board.
Laura joins at an exciting time for the Company as we continue our consolidation strategy via organic growth and strategic acquisition, our first commercial deal for our lead asset signed during the Summer.
As we prepare for the next stage of our future we are pleased to complete our Board structure and wish Laura much success.”
Laura Brogden commented:
“I feel very fortunate to join Incanthera’s team.
Having known the Company for many years, I am thrilled to take the position at such a pivotal and exciting time, and I am very much looking forward to the plans ahead in the immediate future.”
For further information, please contact:
Tim McCarthy, Chairman 07831 675747
Simon Ward, Chief Executive Officer 07747 625506
Montgomery Communications
Suzanne Brocks 07776 234600
Notes to Editors
Established in 2010, Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.
Operating from Manchester, with research facilities in Bradford and Salford, Incanthera was established from the University of Bradford’s Institute of Cancer Therapeutics (www.cancer.brad.ac.uk) to develop oncology treatments from a low cost base via a productive pipeline of early stage technology opportunities.
Managed by a team of experienced individuals drawn from commercial, scientific and regulatory backgrounds, the team also has experience in the establishment, growth and exit of small to medium sized companies.
The website at www.incanthera.com has been designed to showcase the Company’s outstanding expertise in cancer therapeutic technologies.